Explore our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts.
Pα+ Psychedelic Patent Analysis: April 2024
This month:
The 4th Annual Psychedelic Therapeutics & Drug Development Conference offers a unique opportunity to delve into the rapidly evolving field of psychedelic science and its potential in healthcare. Plenary talks and panel sessions will see a wide range of topics covered including drug scheduling, the future of psychedelic science, clinical trial design, research protocols, pain and psychedelics and precision medicine in mental health care.
May 23-24, Boston
“The staff of Lucid News is deeply saddened by the death on Sunday of our friend and colleague Ken Jordan. In addition to being our Editorial Director and co-founder of Lucid News, Ken was a true pioneer and leader in the psychedelic movement and a dear friend to many of us. He had a clear vision of the future of psychedelic communities and dedicated his life to the transformative power of psychedelics for worldwide healing.”
We at Psychedelic Alpha share in this deep sadness. If you would like to honour Ken’s legacy, please consider donating to Lucid News.
MAPS (the nonprofit) issued a statement in response.
“A psychoactive brew prepared from vines by the people of the western Amazon basin, ayahuasca is seen, depending on the version, as a miracle cure, a tool for inner exploration and personal development, a recreational hallucinogen, or a dangerous psychotropic drug.”
The Pathways to Access Summit (Paths) takes place a day prior to ICPR in Haarlem, the Netherlands. The full-day Summit convenes key stakeholders from Europe and beyond to explore the opportunities and challenges around the development, approval, and eventual integration of psychedelic medicines into mainstream European health care.
June 5, Haarlem (the Netherlands)
Pα+: FDA Advisory Committee to Review Lykos Therapeutics’ MDMA-Assisted Therapy in Early June
Next month, the first psychedelic-assisted therapy will be put before an FDA Advisory Committee as Lykos Therapeutics’ MDMA-AT gets a June 4th slot.
“Psychedelic-assisted therapies have been hailed as the wave of the future. They’re also becoming big business. What if most people can’t afford them?”
“I am in favor of legalization of all drugs, primarily psychedelics. If it takes having psychedelics legalized for therapeutic use, then I’m all in for that also.”
“The idea that all of a sudden, wow, instead of having to take a pill every day, a single dose of psilocybin or MDMA could have this profound effect on a chronic illness—it’s pretty cool,” said former NIMH Director Thomas Insel.
The 4th Annual Psychedelic Therapeutics & Drug Development Conference offers a unique opportunity to delve into the rapidly evolving field of psychedelic science and its potential in healthcare. Plenary talks and panel sessions will see a wide range of topics covered including drug scheduling, the future of psychedelic science, clinical trial design, research protocols, pain and psychedelics and precision medicine in mental health care.
May 23-24, Boston
See NCT06309277 for more.
“I feel incredibly lucky to see the change that I’ve been working for happen in my own lifetime,” Doblin says. “I can die happy, whenever that comes around.”
“The [Australian] federal government will spend $3.8 million on the trial involving about 200 survivors of the record-breaking floods that hit the region in 2022.”
“Ernesto Londoño’s memoir ‘Trippy’ explores psychiatry’s renewed flirtation with drugs such as LSD. He’s a believer but not a zealot.”
For more, read Josh’s interview with Londoño.
“A rare condition called hallucinogen persisting perception disorder has puzzled researchers and raised alarms as psychedelics go mainstream.”
“The stepped care treatments in this clinical trial will include an arts-based group compassion program and group-based MDMA-assisted therapy. It is hoped the findings will provide additional treatment options for those impacted by future disasters.”
“Psychedelics are included, a field that Nelsen said ARCH has an interest in. He said that there’s more scientific rigor needed to really dig into how psychedelics work but that the mechanisms of action are intriguing.”
BrainFutures’ latest report “focuses on the critical intersection between the Mental Health Parity and Addiction Equity Act (MHPAEA) and psychedelic-assisted therapy (PAT), offering insights into how this law can help pave the way for comprehensive insurance coverage and access to PAT for those who stand to benefit.”
“She was an enthusiastic supporter of the counterculture. And when she suggested that her brothers rent Mr. Leary a mansion, she made psychedelic history.”
Free subscribers receive a weekly round-up of news on psychedelics, as well as the occasional article.
Receive regular bulletins, articles, interviews with insiders and quick-take analysis of major stories and developments.
Teams, groups and corporate pricing plans are available, please get in touch via email to learn more.
Front-row access to the psychedelics space: breaking bulletins, in-depth articles, insider interviews and sharp analysis of the moments that matter—from major trial results and funding rounds to policy shifts shaping the future. Plus, full access to our complete archive and Library.
Learn More| Free | ||
|---|---|---|
| Weekly Psychedelic News Feed | ||
| Occasional Articles & Free Resources | ||
| Psychedelic Bulletins (In-Depth Briefings, Multiple per Month) | ||
| Quick-Take Analysis of Major Developments | ||
| In-Depth Articles & Deep Dives | ||
| Exclusive Interviews with Insiders & KOLs | ||
| Quarterly Video Briefings | ||
| Exclusive Tools & Data Resources | ||
| Library of Primers & Explainers | ||
|
Subscribe Now |
||
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
By signing up, you agree to our privacy policy. You can unsubscribe at any time.
Aside from group pricing, we also offer bespoke reports and regular briefings. Get in touch to discuss.